A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death.
Mannion J, Gifford V, Bellenie B, Fernando W, Ramos Garcia L, Wilson R, John SW, Udainiya S, Patin EC, Tiu C, et al. Immunity. 2024 Jul 9; 57(7):1514-1532.e15. Epub 2024 May 23.